Evaluation of Omicron Variant to Ensure Test Effectiveness
Evaluation of Omicron Variant to Ensure Test Effectiveness

7th December 2021
Evaluating Omicron and Other SARS-CoV-2 Variants to Ensure Test Effectiveness
SARS-CoV-2, like all viruses, evolves over time through mutations, as it spreads and replicates. Since the beginning of the COVID-19 pandemic, many variants of the SARS-CoV-2 virus, with different sets of mutations, have been observed worldwide. Most changes have little impact on the virus’ properties. However, some may cause increased transmissibility, severity of disease or the ability to evade the host immune response. Surveillance of genetic variations is therefore crucial to identify those variants which pose a higher risk to human health.
Variants may impact the performance of current diagnostic approaches. This is why Randox continuously review public genomic databases to assess whether any emerging mutations overlap with the assay design and monitor assay performance as part of post-market surveillance efforts to ensure the coronavirus assays continue to meet the highest quality standards.
In light of the emergence of the new variant of concern detected in South Africa, Omicron (B.1.1.529), Randox have analysed all publicly available sequences of the variant to predict any impact of defining mutations on assay designs.
As the COVID-19 assays from Randox Laboratories Ltd. are designed using a dual-target approach (ORf1ab, E gene) to reduce the impact of genetic variation in the SARS-CoV-2 genome, detection of SARS-CoV-2 is not predicted to be affected by the currently known variants.
Detection of SARS-CoV-2 using the Vivalytic rapid RT-PCR tests, targeting the E gene sequence are not affected by the identified mutations. Assay performance is not predicted to be impaired by the current known variants.
Randox Laboratories Ltd., in collaboration with leading technology manufacturer Bosch Healthcare Solutions, have developed a range of COVID-19 testing solutions, providing clear and concise results in a timely manner, directly at the point of care. Randox is a distributor for Vivalytic platform and cartridges.
For all enquiries regarding our COVID-19 assays performance , please contact marketing@randox.com
Randox in the media
Latest News
FAQs
Archives
- May 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- June 2014